Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

Analysts are intrested in these 5 stocks: ( ($PYPL) ), ( ($SOUN) ), ( ($MRNA) ), ( ($DVN) ) and ( ($BMY) ). Here is a breakdown of their recent


PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts

An announcement from Nuran Wireless ( ($TSE:NUR) ) is now available. NuRAN Wireless Inc. has announced a consolidation of its common shares at a ra...

NuRAN Wireless Announces Share Consolidation and Restructuring Plan

The SPDR S&P 500 ETF Trust ($SPY) was up 0.07% on Thursday, logging its third consecutive day of gains. Its performance was impacted by mixed labor...

SPY ETF Daily Update, 12/4/2025

The SPDR S&P 500 ETF Trust ($SPY) gained 0.35% on Wednesday, with support from the strong performance of certain stocks such as Tesla ($TSLA), Unit...

SPY ETF Daily Update, 12/3/2025

The Vanguard S&P 500 ETF ($VOO) gained 0.17% on Tuesday as bond yields and Bitcoin stabilized after sharp moves in the previous session. Also, the ...

Vanguard S&P 500 ETF (VOO) Daily Update, 12/3/2025

In a report released today, Courtney Breen from Bernstein maintained a Hold rating on Moderna, with a price target of $25.00. Breen covers the Heal...

Moderna (MRNA) Gets a Hold from Bernstein

Shares of major COVID-19 vaccine makers, Moderna ($MRNA), BioNTech ($BNTX), and Novavax ($NVAX) fell 6%, 5%, and 4%, respectively, on Monday. The d...

MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today

Everything to Know about Macro and Markets U.S. stocks ended the week higher as markets cheered signs of slower inflation and rising odds of a Fede...

The Week That Was, The Week Ahead: Macro & Markets, November 30

The SPDR S&P 500 ETF Trust ($SPY) gained 0.55% on Friday, primarily driven by a rally in chip stocks, optimism about potential future Federal Reser...

SPY ETF Daily Update, 11/28/2025

The Vanguard S&P 500 ETF ($VOO) rose 0.93% on Wednesday, supported by renewed optimism over possible Federal Reserve rate cuts and strength in tech...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/27/2025

Analysts fell to the sidelines weighing in on Moderna (MRNA – Research Report) and Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research...

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

An announcement from Nuran Wireless ( ($TSE:NUR) ) is now available. NuRAN Wireless has successfully closed a non-brokered private placement financ...

NuRAN Wireless Secures CA$ 300,000 in Private Placement for Restructuring

The Vanguard S&P 500 ETF ($VOO) rose 0.93% on Tuesday, supported by growing expectations of Federal Reserve rate cuts and upbeat earnings from reta...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/26/2025

In a report released today, William Pickering from Bernstein maintained a Hold rating on Avidity Biosciences, with a price target of $72.00. Accord...

Bernstein Sticks to Its Hold Rating for Avidity Biosciences (RNA)

The SPDR S&P 500 ETF Trust ($SPY) rose 0.99% on Friday, as the New York Fed President John Williams’ speech revived hopes of an interest rate cut i...

SPY ETF Daily Update, 11/24/2025

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics Limited has announced the appointment of Julian Barbaczy as a...

Alterity Therapeutics Appoints New Director with No Initial Securities Interest

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics Limited has announced the appointment of David Stamler as a...

Alterity Therapeutics Announces New Director Appointment and Securities Interests

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an announcement. Alterity Therapeutics Limited announced the cessation of Brian Meltzer as a dire...

Alterity Therapeutics Announces Director Change

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics Limited has announced that Geoffrey Kempler has ceas...

Alterity Therapeutics Announces Director Departure

In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $28.00. According to TipRank...

Evercore ISI Remains a Hold on Moderna (MRNA)

RBC Capital analyst Luca Issi reiterated a Hold rating on Moderna yesterday and set a price target of $25.00. The company’s shares closed yesterday...

RBC Capital Reaffirms Their Hold Rating on Moderna (MRNA)

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlig...

Alterity Therapeutics Advances in Neurodegenerative Disease Treatment

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, ...

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has announced significant changes to its Board of ...

Alterity Therapeutics Announces Board Restructuring for Growth

The Vanguard S&P 500 ETF ($VOO) gained 0.36% on Wednesday, snapping a four-day slide. The ETF is also up 1.10% in pre-market trading today after Nv...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/20/2025

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year and over 85% in three...

Moderna Stock (MRNA) Faces a Cash Crunch Test as Analyst Day Arrives

Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)

The SPDR S&P 500 ETF Trust ($SPY) closed 0.02% lower on Friday. Volatility in the technology sector and concerns about a potential delay in Federal...

SPY ETF Daily Update, 11/14/2025

In a report released today, Martin Fan from Wedbush maintained a Buy rating on Cartesian Therapeutics, with a price target of $38.00. Fan covers th...

Wedbush Remains a Buy on Cartesian Therapeutics (RNAC)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Cartesian Therapeutics, with a price target of $1...

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Moderna ( ($MRNA) ) has provided an update. On November 12, 2025, Moderna, Inc. held a Special Meeting of Shareholders where two proposals were app...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$71.83	+0.32%	1.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$71.83	+0.3%	1.78M
3
4
5
6

RNA

RNA

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel